Literature DB >> 21527106

Accuracy performance of the Medtronic NexSensor™ for 6 days in an inpatient setting using abdomen and buttocks insertion sites.

Tim Peoples1, Timothy Bailey, Brazg Ronald, Howard C Zisser, Bob Janowski, Suiying Huang, Cary Talbot, Qingqing Yang.   

Abstract

BACKGROUND: Users of continuous glucose monitoring are concerned with product accuracy and choice of insertion site. The Medtronic NexSensor™ was evaluated for accuracy during 6 days of wear when inserted in the abdomen and buttocks areas.
METHODS: Adults (ages 18-75) with type 1 diabetes wore two sensors simultaneously for 6 days, one each inserted in the abdomen and buttocks. Subjects underwent a frequent blood sampling study for 12 hours, during which time reference blood glucose values were obtained every 15 minutes and compared to sensor values.
RESULTS: Sixty-three subjects were enrolled, and 61 subjects completed the study. The mean agreement rate between sensor and blood glucose values was 75.5% [95% confidence interval (CI), 69.5, 81.4] at the abdomen site, 73.8% (95% CI, 68.8, 78.8) at the buttocks site, and 75.6% (95% CI, 70.8, 80.4) when sensor and reference data were combined between sites. Over 90% of paired sensor-reference values on Clarke error grids were within the A and B ranges. The mean absolute relative differences were 17.1% at the abdomen site, 16.5% at the buttocks site, and 16.8% when sites were combined.
CONCLUSION: The NexSensor was accurate for inpatient, frequent-sample testing for 6 days when inserted into the abdomen and buttocks. The results of this study also provide evidence that both the abdomen and buttocks are suitable as sensor insertion sites.
© 2011 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21527106      PMCID: PMC3125929          DOI: 10.1177/193229681100500224

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  12 in total

1.  Comparison of the numerical and clinical accuracy of four continuous glucose monitors.

Authors:  Boris Kovatchev; Stacey Anderson; Lutz Heinemann; William Clarke
Journal:  Diabetes Care       Date:  2008-03-13       Impact factor: 19.112

Review 2.  Delays in minimally invasive continuous glucose monitoring devices: a review of current technology.

Authors:  D Barry Keenan; John J Mastrototaro; Gayane Voskanyan; Garry M Steil
Journal:  J Diabetes Sci Technol       Date:  2009-09-01

3.  Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements.

Authors:  Howard C Zisser; Timothy S Bailey; Sherwyn Schwartz; Robert E Ratner; Jonathan Wise
Journal:  J Diabetes Sci Technol       Date:  2009-09-01

4.  Evaluating clinical accuracy of systems for self-monitoring of blood glucose.

Authors:  W L Clarke; D Cox; L A Gonder-Frederick; W Carter; S L Pohl
Journal:  Diabetes Care       Date:  1987 Sep-Oct       Impact factor: 19.112

5.  Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.

Authors:  Richard M Bergenstal; William V Tamborlane; Andrew Ahmann; John B Buse; George Dailey; Stephen N Davis; Carol Joyce; Tim Peoples; Bruce A Perkins; John B Welsh; Steven M Willi; Michael A Wood
Journal:  N Engl J Med       Date:  2010-06-29       Impact factor: 91.245

6.  Putative delays in interstitial fluid (ISF) glucose kinetics can be attributed to the glucose sensing systems used to measure them rather than the delay in ISF glucose itself.

Authors:  Gayane Voskanyan; D Barry Keenan; John J Mastrototaro; Garry M Steil
Journal:  J Diabetes Sci Technol       Date:  2007-09

7.  Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system.

Authors:  Bruce Bode; Kenneth Gross; Nancy Rikalo; Sherwyn Schwartz; Timothy Wahl; Casey Page; Todd Gross; John Mastrototaro
Journal:  Diabetes Technol Ther       Date:  2004-04       Impact factor: 6.118

8.  Continuous glucose monitoring and intensive treatment of type 1 diabetes.

Authors:  William V Tamborlane; Roy W Beck; Bruce W Bode; Bruce Buckingham; H Peter Chase; Robert Clemons; Rosanna Fiallo-Scharer; Larry A Fox; Lisa K Gilliam; Irl B Hirsch; Elbert S Huang; Craig Kollman; Aaron J Kowalski; Lori Laffel; Jean M Lawrence; Joyce Lee; Nelly Mauras; Michael O'Grady; Katrina J Ruedy; Michael Tansey; Eva Tsalikian; Stuart Weinzimer; Darrell M Wilson; Howard Wolpert; Tim Wysocki; Dongyuan Xing
Journal:  N Engl J Med       Date:  2008-09-08       Impact factor: 91.245

9.  Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems.

Authors:  Satish K Garg; James Smith; Christie Beatson; Benita Lopez-Baca; Mary Voelmle; Peter A Gottlieb
Journal:  Diabetes Technol Ther       Date:  2009-02       Impact factor: 6.118

10.  Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes.

Authors:  Roy W Beck; Bruce Buckingham; Kellee Miller; Howard Wolpert; Dongyuan Xing; Jennifer M Block; H Peter Chase; Irl Hirsch; Craig Kollman; Lori Laffel; Jean M Lawrence; Kerry Milaszewski; Katrina J Ruedy; William V Tamborlane
Journal:  Diabetes Care       Date:  2009-08-12       Impact factor: 19.112

View more
  1 in total

1.  Analysis: accuracy performance of the Medtronic NexSensor for 6 days in an inpatient setting using abdomen and buttocks insertion sites.

Authors:  Mariela Glandt; Itamar Raz
Journal:  J Diabetes Sci Technol       Date:  2011-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.